

August 4, 2008




## Inside Wall Street

### A Biotech's Overseas Pacts

Roche Holding's ([RHHBY](#)) bid to buy all of Genentech ([DNA](#)) has reignited investor interest in U.S. biotechs, especially those that are already partnered with foreign drugmakers. One such is Emisphere Technologies ([EMIS](#)), whose Eligen technology, which allows more drugs to be taken by mouth, is being tested by Switzerland's Novartis ([NVS](#)) for its drug for osteoporosis and osteoarthritis. In June, Denmark's Novo Nordisk ([NVO](#)), a major insulin producer, teamed up with Emisphere to develop an oral formulation of Novo's diabetes medicines. Novo will pay as much as \$87 million for Emisphere's technology.

#### EMISPHERE: GOOD WORD OF MOUTH



Data: Bloomberg Financial Markets

Stephen Brozak, president of WBB Securities, rates Emisphere, now at 2.89 a share, a buy, with a 12-month target of 7.50. "Emisphere's Eligen has the potential for wider applications," says Brozak. Also bullish: Amy Wang of MDB Capital, who has a 12-month target of 7.

*Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.*

*Marcial writes the Inside Wall Street column for BusinessWeek. In 2008, FT Press published the book [Gene Marcial's 7 Commandments of Stock Investing](#).*

—By Gene Marcial